nonarteritic anterior ischemic optic neuropathy semaglutide NAION Network Study Announcement A new study suggests patients

Securing an oral or poster presentation at the prestigious ADA sessions highlights the medical community's interest in efsubaglutide alfa as a competitive, convenient weekly or monthly treatment alternative in a highly dynamic metabolic disease market

Over time, untreated OSA can increase the risk of heart disease, hypertension, and metabolic dysfunction

Stop at Satisfied, Not Full Learn the difference between "I could eat more" and "I'm satisfied." On GLP-1s, the jump from satisfied to uncomfortably full happens very quickly with just a few more bites

7.2 Challenges Antioxidants demonstrate unique potential in improving obesity and treating endometrial pathologies

Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in psammomys obesusan adaptive response to hyperglycaemia